Seres Therapeutics MCRB Stock
Seres Therapeutics Price Chart
Seres Therapeutics MCRB Financial and Trading Overview
Seres Therapeutics stock price | 0.64 USD |
Previous Close | 6.12 USD |
Open | 6.08 USD |
Bid | 0 USD x 3100 |
Ask | 0 USD x 4000 |
Day's Range | 5.72 - 6.1 USD |
52 Week Range | 2.74 - 9.49 USD |
Volume | 2.26M USD |
Avg. Volume | 3.25M USD |
Market Cap | 731.59M USD |
Beta (5Y Monthly) | 2.63169 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.81 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11 USD |
MCRB Valuation Measures
Enterprise Value | 787.76M USD |
Trailing P/E | N/A |
Forward P/E | -4.028169 |
PEG Ratio (5 yr expected) | 0.05 |
Price/Sales (ttm) | 143.085 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 154.07 |
Enterprise Value/EBITDA | -3.091 |
Trading Information
Seres Therapeutics Stock Price History
Beta (5Y Monthly) | 2.63169 |
52-Week Change | 100.00% |
S&P500 52-Week Change | 20.43% |
52 Week High | 9.49 USD |
52 Week Low | 2.74 USD |
50-Day Moving Average | 5.47 USD |
200-Day Moving Average | 5.93 USD |
MCRB Share Statistics
Avg. Volume (3 month) | 3.25M USD |
Avg. Daily Volume (10-Days) | 3.03M USD |
Shares Outstanding | 127.9M |
Float | 96.22M |
Short Ratio | 4.93 |
% Held by Insiders | 6.72% |
% Held by Institutions | 83.81% |
Shares Short | 15.52M |
Short % of Float | 23.03% |
Short % of Shares Outstanding | 12.13% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -5110.64% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -55.35% |
Return on Equity (ttm) | -1600.16% |
Income Statement
Revenue (ttm) | 5.11M USD |
Revenue Per Share (ttm) | 0.04 USD |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | -165792000 USD |
EBITDA | -254848000 USD |
Net Income Avi to Common (ttm) | -264707008 USD |
Diluted EPS (ttm) | -2.27 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 106.54M USD |
Total Cash Per Share (mrq) | 0.83 USD |
Total Debt (mrq) | 162.71M USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 1.819 |
Book Value Per Share (mrq) | -0.378 |
Cash Flow Statement
Operating Cash Flow (ttm) | -238955008 USD |
Levered Free Cash Flow (ttm) | -154958880 USD |
Profile of Seres Therapeutics
Country | United States |
State | MA |
City | Cambridge |
Address | 200 Sidney Street |
ZIP | 02139 |
Phone | 617 945 9626 |
Website | https://www.serestherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 431 |
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Q&A For Seres Therapeutics Stock
What is a current MCRB stock price?
Seres Therapeutics MCRB stock price today per share is 0.64 USD.
How to purchase Seres Therapeutics stock?
You can buy MCRB shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Seres Therapeutics?
The stock symbol or ticker of Seres Therapeutics is MCRB.
Which industry does the Seres Therapeutics company belong to?
The Seres Therapeutics industry is Biotechnology.
How many shares does Seres Therapeutics have in circulation?
The max supply of Seres Therapeutics shares is 174.36M.
What is Seres Therapeutics Price to Earnings Ratio (PE Ratio)?
Seres Therapeutics PE Ratio is now.
What was Seres Therapeutics earnings per share over the trailing 12 months (TTM)?
Seres Therapeutics EPS is -0.81 USD over the trailing 12 months.
Which sector does the Seres Therapeutics company belong to?
The Seres Therapeutics sector is Healthcare.
Seres Therapeutics MCRB included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
NASDAQ Biotechnology Total Retu XNBI | 4224.19 USD — |
-5.49
|
— — | 4221.36 USD — | 4397.83 USD — | — - | — — |
NASDAQ Global Select Market Com NQGS | 7625.89 USD — |
-5.84
|
— — | 7621.56 USD — | 7894.21 USD — | — - | — — |
NASDAQ Biotechnology NBI | 3904.12 USD — |
-5.49
|
— — | 3901.51 USD — | 4064.61 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 19079.55 USD — |
-5.82
|
— — | 19064.73 USD — | 19740.96 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}